Rocket Pharmaceuticals, Inc.
A developer of gene therapies for rare, life-threatening genetic diseases, Rocket Pharmaceuticals works to correct the underlying genetic defects behind conditions like Danon disease and leukocyte adhesion deficiency. Founded in 2015 and merged with Inotek Pharmaceuticals in 2018, the company's name reflects its "moonshot" ambition to bring speed to medicine. Its therapies either modify a patient's own blood stem cells outside the body or deliver corrected genes directly via engineered viruses.
Granted 362.5K · Sold 85.4K
Granted 561.8K · Sold 19.3K
Granted 62.0K
Granted 407.9K
Granted 80.0K · Sold 2.5K
Granted 125.9K · Sold 17.6K
Granted 70.0K · Sold 36.1K
Granted 53.3K
Bought 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Wong Roderick +1 co-filerDirector, 10% owner, See remarks, Director, 10% owner, See Remarks · 6 transactions | — | 18.30M | — | — | — |
| Shah GauravCEO · 8 transactions | +28% | 1.52M | 362.5K | — | 85.4K |
| Wilson MartinGeneral Counsel · 8 transactions | +400.5% | 678.0K | 561.8K | — | 19.3K |
| Stevens Christopher JamesChief Operating Officer · 1 transaction | +15.2% | 469.1K | 62.0K | — | — |
| Rizvi Syed Ali-aamirChief Medical Officer · 3 transactions | — | 407.9K | 407.9K | — | — |
| Schwartz Jonathan DavidSee Remarks · 2 transactions | +35% | 299.1K | 80.0K | — | 2.5K |
| Chaudhuri SarbaniSee Remarks · 2 transactions | — | 267.5K | 125.9K | — | 17.6K |
| Militello JohnSee Remarks · 11 transactions | +60.5% | 89.8K | 70.0K | — | 36.1K |
| Fong PeterDirector · 2 transactions | — | 53.3K | 53.3K | — | — |
| Bjork ElisabethDirector · 1 transaction | +25% | 50.0K | — | 10.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -151.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.